Contact us
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...
The latest news, blog posts, and podcasts featuring Angiex
07 August 2024
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
11 October 2024
Angiex was featured as one of a select few companies in Labiotech’s article on building successful biotech startups. CEO Paul Jaminet shared insights on the advantages of Cambridge’s biotech ecosystem.
07 October 2024
Angiex is featured in Drug Discovery World as a leading North American biotech innovator. CEO Paul Jaminet discusses the critical role of Cambridge’s infrastructure in the company’s early success and its development of TM4SF1-directed ADCs.
15 August 2024
Angiex doses the first patient in its Phase 1 trial of a novel antibody-drug conjugate (ADC) therapy targeting blood vessels in tumors, marking a significant milestone in cancer treatment development
25 November 2024
Welcome to the Angiex Founder's Blog
31 October 2024
Watch Angiex CEO Dr. Paul Jaminet and founder Dr. Harold Dvorak, a leading authority on angiogenesis, present at a Force Family Office webinar. This engaging session offers an inside look at Angiex’s development of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to target both tumor cells and the blood vessels that feed them
20 September 2024
Join Angiex CEO Dr. Paul Jaminet as he presents at the MedInvest 2024 October Meeting, offering a comprehensive overview of AGX101, the company’s first-in-class TM4SF1-directed antibody-drug conjugate (ADC).
08 September 2024
Angiex's CEO, Paul Jaminet, discusses the company’s innovative approach to cancer therapies, including their focus on TM4SF1-targeted ADCs, and the challenges and opportunities in advancing breakthrough treatments.
13 January 2025
More details and link to download poster coming soon...
17 November 2024
Taking place November 17-20, 2024 in Boston, Massachusetts, will feature a poster presentation by Angiex, titled “AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial.”
07 May 2024
Angiex founder publishes paper describing the TM4SF1 intracellular transport pathway utilized by AGX101
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...